Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
Authors
Keywords
-
Journal
LIVER INTERNATIONAL
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-11-15
DOI
10.1111/liv.14731
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference
- (2020) Josep M. Llovet et al. HEPATOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Insights into the success and failure of systemic therapy for hepatocellular carcinoma
- (2019) Jordi Bruix et al. Nature Reviews Gastroenterology & Hepatology
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
- (2018) Lorenza Rimassa et al. LANCET ONCOLOGY
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo.
- (2017) Jordi Bruix et al. JOURNAL OF CLINICAL ONCOLOGY
- Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
- (2017) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib
- (2016) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib
- (2015) Massimo Iavarone et al. HEPATOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
- (2013) Takahide Nakazawa et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- HCC and angiogenesis: possible targets and future directions
- (2011) Andrew X. Zhu et al. Nature Reviews Clinical Oncology
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now